Premium
Continuation treatment with escitalopram reduces body dysmorphic disorder relapse
Publication year - 2016
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30155
Subject(s) - escitalopram , body dysmorphic disorder , placebo , medicine , continuation , psychosocial , psychiatry , anxiety , alternative medicine , pathology , computer science , antidepressant , programming language
In what is believed to be the first relapse prevention study in body dysmorphic disorder (BDD), researchers found that 6 months of continuation treatment with escitalopram resulted in fewer relapses and an increased time to relapse when compared with placebo. However, patients receiving escitalopram in the study's continuation phase did not see significant improvement in psychosocial functioning or quality of life when compared with placebo patients, the researchers reported.